| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $5.8M | -51.6% |
| SG&A Expense | $9.3M | -6.1% |
| Operating Income | -$15.1M | +30.9% |
| Net Income | -$293.4M | — |
| EPS (Basic) | -$34.67 | — |
| EPS (Diluted) | -$34.67 | — |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $82.3M | +285.3% |
| Current Assets | $83.1M | +273.2% |
| Total Assets | $98.0M | +163.8% |
| Current Liabilities | $2.3M | -19.3% |
| Total Liabilities | $233.8M | +272.0% |
| Stockholders' Equity | -$140.7M | -447.8% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$13.5M | +30.9% |
| Investing Cash Flow | $0 | — |
| Financing Cash Flow | $74.5M | — |